OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Shah on the Efficacy and Safety of Cilta-Cel in Relapsed/Refractory Multiple Myeloma

April 28th 2021

Nina Shah, MD, discusses the efficacy and safety data observed with ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

Dr. Devitt on Utilizing PD-L1 in Biomarker-Guided Therapies in Bladder Cancer

April 28th 2021

Michael Devitt, MD, discusses utilizing PD-L1 status in biomarker-guided therapies for patients with bladder cancer.

Dr. Grunwald on the Efficacy of 19-28z CAR T-Cell Therapy in B-ALL

April 27th 2021

Michael R. Grunwald, MD, FACP, discusses the efficacy of 19-28z CAR T-cell therapy in B-cell acute lymphoblastic leukemia.

Dr. Rapisuwon on Frontline Immunotherapy Vs Targeted Therapy in Melanoma Subtypes

April 27th 2021

Suthee Rapisuwon, MD, discusses the utility of frontline immunotherapy vs targeted therapy in acral and mucosal melanoma.

Dr. Miller on the Potential Utility of Sequential PARP Inhibition in Ovarian Cancer

April 27th 2021

Eirwen M. Miller, MD, discusses the potential utility of sequential PARP inhibition in ovarian cancer.

Dr. Mohindra on the Impact of Lurbinectedin in SCLC

April 27th 2021

Nisha A. Mohindra, MD, discusses the impact of the FDA approval of lurbinectedin in the treatment of patients with small cell lung cancer.

Dr. Rini on the Mechanism of Action of Tivozanib in Relapsed/Refractory RCC

April 26th 2021

Brian I. Rini, MD, discusses the mechanism of action of tivozanib in relapsed/refractory renal cell carcinoma.

Dr. Usmani on the Potential Future of Isatuximab in Multiple Myeloma

April 26th 2021

Saad Z. Usmani, MD, FACP, discusses the potential future utility of isatuximab-irfc in multiple myeloma.

Dr. Raz on the Effects of COVID-19 on Lung Cancer Screening

April 26th 2021

Dan J. Raz, MAS, MD, discusses the effects of COVID-19 on lung cancer screening.

Dr. Choudhury on Future Research Directions for Pembrolizumab/Radium-223 in mCRPC

April 26th 2021

Atish D. Choudhury, MD, PhD, discusses future research directions for the combination of pembrolizumab and radium-223 dichloride in patients with metastatic castration-resistant prostate cancer.

Dr. Shadman on the Emergence of Third-Generation BTK Inhibitors in CLL

April 23rd 2021

Mazyar Shadman, MD, discusses the emergence of third-generation BTK inhibitors in chronic lymphocytic leukemia.

Dr. Ward on Considerations for Salvage Radiation Therapy in Prostate Cancer

April 23rd 2021

Matthew C. Ward, MD, discusses considerations for salvage radiation therapy in prostate cancer.

Dr. Shah on Future Directions With CAR T-Cell Therapy in Multiple Myeloma

April 23rd 2021

Nina Shah, MD, discusses potential future directions with CAR T-cell therapy in multiple myeloma.

Dr. Tewari on Key Differences Between Racial Subgroups in Prostate Cancer

April 23rd 2021

Ashutosh K. Tewari, MD, discusses some of the key differences between racial subgroups in prostate cancer.

Dr. Hahn on Future Research Directions with Tucatinib in Breast Cancer

April 23rd 2021

Olwen Hahn, MD, discusses future research directions with tucatinib (Tukysa) in the treatment of patients with breast cancer.

Dr. Tewari on the Hallmarks of Cancer in Black Men With Prostate Cancer

April 22nd 2021

Ashutosh K. Tewari, MD, discusses the hallmarks of cancer among Black men with prostate cancer.

Dr. Vij on the Integration of Selinexor in Relapsed/Refractory Multiple Myeloma

April 22nd 2021

Ravi Vij, MD, MBA, discusses the integration of selinexor into the relapsed/refractory multiple myeloma armamentarium.

Dr. Burgess on the FDA Accelerated Approval of Rucaparib in BRCA+ mCRPC

April 22nd 2021

Earle Burgess, MD, discusses the FDA accelerated approval of rucaparib in BRCA-positive metastatic castration-resistant prostate cancer.

Dr. Skarbnik on the Optimization of CAR T-Cell Therapy Sequencing in MCL

April 22nd 2021

Alan P. Z. Skarbnik, MD, discusses the optimization of treatment sequencing with CAR T-cell therapy in mantle cell lymphoma.

Dr. Tewari on the Potential Benefits of a Mobile MRI Unit in Prostate Cancer

April 21st 2021

Ashutosh K. Tewari, MD, director, Department of Urology, Mount Sinai, discusses the potential benefits of a mobile MRI unit in prostate cancer.